bpc-157 clinical trial august 2025 BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1 | Cell Communication and Signaling Sample of patents with BPC

Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H, Fellermann K, Ganz T, Stange EF, Bevins CL: Reduced Paneth cell -defensins in ileal Crohn's disease

The peptide comes in lyophilized (freeze-dried) powder form and needs to be reconstituted with bacteriostatic water before use

Orforglipron Orforglipron is a once-daily, oral, non-peptide GLP-1 RA (small molecule) which interacts with the GLP-1 receptor in a slightly different manner compared to native GLP-1

It reduces inflammation, stimulates cell growth, and increases blood flow to the injured area, creating an optimal environment for tissue repair

Activation of this pathway increases the cells ability to neutralize ROS before they can damage proteins, lipids, or DNA

Talking to your doctor about your supplements is a must if youre on immunotherapy